XGN
HEALTHCAREExagen Inc
$3.09+0.00 (+0.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving XGN Today?
No stock-specific AI insight has been generated for XGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.59$12.23
$3.09
Fundamentals
Market Cap$75M
P/E Ratio—
EPS$-0.93
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume251K
Avg Volume (10D)—
Shares Outstanding24.1M
XGN News
20 articles- AtriCure (ATRC) Reports Break-Even Earnings for Q1Yahoo Finance·May 5, 2026
- Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026Yahoo Finance·Apr 27, 2026
- Does Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?Yahoo Finance·Apr 12, 2026
- How Analyst Resets Are Reshaping The Exagen (XGN) Investment StoryYahoo Finance·Mar 27, 2026
- Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic InvestmentsYahoo Finance·Mar 10, 2026
- Exagen Q4 Earnings Call HighlightsMarketbeat·Mar 10, 2026
- Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 10, 2026
- Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 ResultsYahoo Finance·Mar 10, 2026
- Exagen Inc. to Participate in Upcoming Investor ConferencesYahoo Finance·Mar 3, 2026
- Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026Yahoo Finance·Feb 24, 2026
- What Analysts Think Is Changing The Story For Exagen (XGN) NowYahoo Finance·Feb 12, 2026
- How The Exagen (XGN) Story Is Shifting With A New Analyst Price TargetYahoo Finance·Jan 27, 2026
- How Recent Analyst Resets Are Reframing The Exagen (XGN) Investment StoryYahoo Finance·Jan 12, 2026
- Exagen Inc. Announces Select Preliminary 2025 Financial ResultsYahoo Finance·Jan 11, 2026
- How the Narrative Surrounding Exagen Is Evolving After New Guidance and Price Target UpgradesYahoo Finance·Dec 22, 2025
- What New Catalysts Are Shaping the Narrative for Exagen?Yahoo Finance·Dec 8, 2025
- Why Analysts Are Updating Exagen’s Story After Higher Targets and Growth OutlookYahoo Finance·Nov 23, 2025
- Exagen Inc. to Participate in Fourth Quarter Investor ConferencesYahoo Finance·Nov 11, 2025
- How Analyst Views Are Shifting the Story for Exagen Amid New Growth SignalsYahoo Finance·Nov 7, 2025
- Exagen (XGN): Revenue Growth Outlook Challenges Bearish Sentiment as Valuation Remains UndemandingYahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
Open$3.14
Previous Close$3.09
Day High$3.25
Day Low$3.03
52 Week High$12.23
52 Week Low$2.59
52-Week Range
$2.59$12.23
$3.09
Fundamentals
Market Cap$75M
P/E Ratio—
EPS$-0.93
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume251K
Avg Volume (10D)—
Shares Outstanding24.1M
About Exagen Inc
Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—